DUBLIN, August 9, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Prostate Cancer" report to their offering.
The value of the prostate cancer market will more than double during 2015-24, reaching $13.5bn in 2024 at a compound annual growth rate (CAGR) of 8.6%.
This report addresses the following questions:
- Which products will drive the growth of the prostate cancer market during 2015-24?
- Which geographic markets will experience the largest growth?
- Which pipeline therapies will have the largest impact on treatment practices in prostate cancer?
- What are the most valuable treatment settings within prostate cancer being targeted by drug developers?
- What is the commercial outlook for current market leaders Xtandi and Zytiga over the forecast period?
Key Topics Covered:
FORECAST: PROSTATE CANCER
- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- DCVAC/PCa
- Galeteronem
- Jevtana (cabazitaxel)
- JNJ-560219
- Lupron (leuprolide)
- Masitinib
- ODM-2
- ProstAtak (AdV-tk + valacyclovir)
- PROSTVAC
- Provenge (sipuleucel-T)
- Taxotere (docetaxel)
- Xofigo (radium-223)
- Xtandi (enzalutamide)
- Zoladex (goserelin)
- Zytiga (abiraterone acetate)
- Primary Research Methodology
TREATMENT: PROSTATE CANCER
- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
EPIDEMIOLOGY: PROSTATE CANCER
- Executive Summary
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations
MARKETED DRUGS: PROSTATE CANCER
- Executive Summary
- Product Overview
- Product profile: Jevtana
- Product profile: Lupron
- Product profile: Provenge
- Product profile: Taxotere
- Product profile: Xofigo
- Product profile: Xtandi
- Product profile: Zytiga
PIPELINE: PROSTATE CANCER
- Executive Summary
- Clinical Pipeline Overview
- Target Product Profile
- Recently Discontinued Drugs
- Clinical Trial Design
- Product profile (late stage): DCVAC/PCa
- Product profile (late stage): JNJ-560219
- Product profile (late stage): ODM-2
- Product profile (late stage): PROSTVAC
- Product profile (late stage): ProstAtak
- Product profile (late stage): galeterone
- Product profile (late stage): masitinib
For more information visit http://www.researchandmarkets.com/research/ttz22z/prostate_cancer
Media Contact:
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article